KBC Group
AGIO icon

KBC Group’s Agios Pharmaceuticals AGIO Stock Holding History

KBC Group’s Portfolio AGIO Stock Details AGIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$70K Sell
2,073
-947
-31% -$26.8K ﹤0.01% 1504
2025
Q4 		$82K Buy
3,020
+1,269
+72% +$44.5K ﹤0.01% 1408
2025
Q3 		$70K Hold
1,751
– – ﹤0.01% 1481
2025
Q2 		$58K Sell
1,751
-864
-33% -$26.2K ﹤0.01% 1530
2025
Q1 		$77K Hold
2,615
– – ﹤0.01% 1615
2024
Q4 		$86K Buy
2,615
+611
+30% +$28.7K ﹤0.01% 1641
2024
Q3 		$89K Hold
2,004
– – ﹤0.01% 1357
2024
Q2 		$86K Buy
+2,004
New +$72.3K ﹤0.01% 1255

Other funds holding AGIO

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
LCM
Lynx1 Capital Management San Juan, Puerto Rico $633M AUM 173.22% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
EAM
Erste Asset Management Vienna, Austria $12.9B AUM 52.69% 1-Year Est. Return
BNP Paribas Asset Management
BNP Paribas Asset Management Paris, France $86.1B AUM 29.11% 1-Year Est. Return

KBC Group's AGIO Position: Q1 2026 in Review

KBC Group reduced its Agios Pharmaceuticals (AGIO) stake by 31% in Q1 2026, selling an estimated $26.8K and leaving 2,073 shares worth $70K. The position accounts for ﹤0.01% of the portfolio, ranked #1504.

KBC Group first reported a position in AGIO in Q2 2024 and has held it in 8 quarters since. The position peaked at $89K in Q3 2024. 233 funds tracked by Wall St. Rank hold AGIO as of Q1 2026.

  • KBC Group held 2,073 shares of Agios Pharmaceuticals worth $70K as of Q1 2026.
  • KBC Group sold 947 Agios Pharmaceuticals shares in Q1 2026, an estimated $26.8K.
  • Agios Pharmaceuticals made up ﹤0.01% of KBC Group's portfolio in Q1 2026, its #1504 holding.
  • KBC Group first reported a position in Agios Pharmaceuticals in Q2 2024 and has held it in 8 quarters since.
  • KBC Group's Agios Pharmaceuticals position peaked at $89K in Q3 2024.
  • 233 funds tracked by Wall St. Rank held Agios Pharmaceuticals as of Q1 2026.

Based on KBC Group's 13F filing for Q1 2026, filed 7 May 2026.